Alessandro Gringeri

Summary

Affiliation: University of Milan
Country: Italy

Publications

  1. ncbi VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study
    A Gringeri
    Department of Medicine and Medical Specialties, A Bianchi Bonomi Haemophilia and Thrombosis Centre, University of Milan, Milan, Italy
    Haemophilia 13:73-7. 2007
  2. ncbi Pharmacotherapy of haemophilia A
    Alessandro Gringeri
    Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, Milan, Italy
    Expert Opin Biol Ther 11:1039-53. 2011
  3. ncbi Long-term aspects of hemophilia B treatment: part II
    Alessandro Gringeri
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital and University of Milan, Italy
    Blood Coagul Fibrinolysis 15:S15-6. 2004
  4. ncbi Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors
    A Gringeri
    Department of Internal Medicine and Dermatology, Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, Milan, Italy
    Haemophilia 11:611-9. 2005
  5. ncbi Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate
    A Gringeri
    Department of Internal Medicine and Dermatology, IRCCS Maggiore Policlinic, Regina Elena, Mangiagalli Hospital Foundation, and Department of Pharmacological Sciences, University of Milan, Italy
    Haemophilia 12:128-32. 2006
  6. ncbi Quality of life assessment in clinical practice in haemophilia treatment
    A Gringeri
    Department of Medicine and Medical Sciences, A Bianchi Bonomi Haemophilia and Thrombosis Centre, University of Milan and IRCCS Maggiore Hospital and Mangiagalli, Regina Elena Foundation, Milan, Italy
    Haemophilia 12:22-9. 2006
  7. ncbi Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response
    A Gringeri
    A Bianchi Bonomi Haemophilia and Thrombosis Centre, Department of Medicine and Medical Specialties, University of Milan and IRCCS Maggiore Hospital, Milan, Italy
    Haemophilia 13:373-9. 2007
  8. ncbi Quality of life in haemophilia
    A Gringeri
    Department of Medicine and Medical Specialities, A Bianchi Bonomi Haemophilia and Thrombosis Centre, University of Milan and IRCCS Maggiore Hospital, Milan, Italy
    Haemophilia 14:19-25. 2008
  9. ncbi A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)
    A Gringeri
    Department of Medicine and Medical Specialities, Fondazione IRCCS Ca Granda, Ospedale Maggiore Policlinico and University of Milan, Milan, Italy
    J Thromb Haemost 9:700-10. 2011
  10. ncbi Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors
    A Gringeri
    Department of Medical Specialities, University of Milan, Milan, Italy
    Haemophilia 17:630-5. 2011

Detail Information

Publications32

  1. ncbi VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study
    A Gringeri
    Department of Medicine and Medical Specialties, A Bianchi Bonomi Haemophilia and Thrombosis Centre, University of Milan, Milan, Italy
    Haemophilia 13:73-7. 2007
    ....
  2. ncbi Pharmacotherapy of haemophilia A
    Alessandro Gringeri
    Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, Milan, Italy
    Expert Opin Biol Ther 11:1039-53. 2011
    ..Prophylaxis with bypassing agents and their use in combination are offering opportunities in management of inhibitor patients. More evidence is necessary to understand how to prevent and manage this complication...
  3. ncbi Long-term aspects of hemophilia B treatment: part II
    Alessandro Gringeri
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital and University of Milan, Italy
    Blood Coagul Fibrinolysis 15:S15-6. 2004
    ..Early results support findings from other studies regarding the benefits of prophylaxis. Prospective pharmacoeconomic evaluations are needed to help define optimal treatment programs for patients with hemophilia A and B...
  4. ncbi Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors
    A Gringeri
    Department of Internal Medicine and Dermatology, Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, Milan, Italy
    Haemophilia 11:611-9. 2005
    ..We report here recommendations and open issues concerning the diagnosis and monitoring of inhibitors, inhibitor eradication and the management of bleeding in patients with haemophilia A and B...
  5. ncbi Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate
    A Gringeri
    Department of Internal Medicine and Dermatology, IRCCS Maggiore Policlinic, Regina Elena, Mangiagalli Hospital Foundation, and Department of Pharmacological Sciences, University of Milan, Italy
    Haemophilia 12:128-32. 2006
    ....
  6. ncbi Quality of life assessment in clinical practice in haemophilia treatment
    A Gringeri
    Department of Medicine and Medical Sciences, A Bianchi Bonomi Haemophilia and Thrombosis Centre, University of Milan and IRCCS Maggiore Hospital and Mangiagalli, Regina Elena Foundation, Milan, Italy
    Haemophilia 12:22-9. 2006
    ....
  7. ncbi Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response
    A Gringeri
    A Bianchi Bonomi Haemophilia and Thrombosis Centre, Department of Medicine and Medical Specialties, University of Milan and IRCCS Maggiore Hospital, Milan, Italy
    Haemophilia 13:373-9. 2007
    ..These findings suggest that high purity VWF/FVIII complex concentrates are effective in ITI, even in patients at high risk of failure...
  8. ncbi Quality of life in haemophilia
    A Gringeri
    Department of Medicine and Medical Specialities, A Bianchi Bonomi Haemophilia and Thrombosis Centre, University of Milan and IRCCS Maggiore Hospital, Milan, Italy
    Haemophilia 14:19-25. 2008
    ....
  9. ncbi A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)
    A Gringeri
    Department of Medicine and Medical Specialities, Fondazione IRCCS Ca Granda, Ospedale Maggiore Policlinico and University of Milan, Milan, Italy
    J Thromb Haemost 9:700-10. 2011
    ....
  10. ncbi Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors
    A Gringeri
    Department of Medical Specialities, University of Milan, Milan, Italy
    Haemophilia 17:630-5. 2011
    ..SCBT was efficacious without adverse events; nevertheless, due to potential risks, it remains a salvage treatment. A prospective clinical trial is needed to provide further evidence...
  11. ncbi Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII
    Alessandro Gringeri
    Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre and Department of Internal Medicine and Dermatology, IRCCS Maggiore Hospital and University of Milan, Milan
    Br J Haematol 126:398-404. 2004
    ..3%). These data indirectly support the views that BDD-rFVIII is equivalent to other rFVIIIs in term of efficacy and inhibitor development...
  12. ncbi Health status and health-related quality of life of children with haemophilia from six West European countries
    A Gringeri
    Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, Department of Internal Medicine, IRCCS Maggiore Hospital and University of Milan, Milan, Italy
    Haemophilia 10:26-33. 2004
    ..Health care of children in Western Europe is progressively improving with a large diffusion of home treatment and prophylaxis. This provides a high level of health status and HRQoL, being better in haemophilic adolescents on prophylaxis...
  13. ncbi Prospective controlled studies on prophylaxis: an Italian approach
    A Gringeri
    Haemophilia and Thrombosis Centre, Department of Internal Medicine, IRCCS Maggiore Hospital and University of Milan, Milan, Italy
    Haemophilia 9:38-42; discussion 43. 2003
    ....
  14. ncbi Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group
    Alessandro Gringeri
    Angelo Bianchi Bonomi Hemphilia and Thrombosis Center, University of Milan, Italy
    Blood 102:2358-63. 2003
    ..This study shows that hemophilia complicated by inhibitors, a prototype of rare disease, requires high amounts of resources for management that provides a satisfactory quality of life...
  15. ncbi Evidence-based recommendations on the treatment of von Willebrand disease in Italy
    Pier Mannuccio Mannucci
    Centro Emofilia e Trombosi Angelo Bianchi Bonomi, Dipartimento di Medicina e Specialità Mediche, Università di Milano e IRCCS Fondazione Ospedale Maggiore, Italy
    Blood Transfus 7:117-26. 2009
    ..The aim of treatment is to correct the dual defect of haemostasis caused by the abnormal/reduced VWF and the concomitant deficiency of factor VIII (FVIII)...
  16. ncbi Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors
    E Santagostino
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine, IRCCS Maggiore Hospital and University of Milan, Italy
    Thromb Haemost 86:954-8. 2001
    ..It also demonstrates that FVII:C levels attained in plasma do not always predict efficacy because similarly high levels were attained during successful treatments and in those that failed...
  17. ncbi [HIV-related thrombocytopenias]
    P M Mannucci
    Dipartimento di Medicina Interna, Centro Emofilia e Trombosi Angelo Bianchi Bonomi, Universita degli Studi di Milano
    Ann Ital Med Int 15:20-7. 2000
    ..On the whole, thrombocytopenia is generally a relatively mild complication of the human immunodeficiency virus infection and aggressive treatment is often unwarranted...
  18. ncbi Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy
    S M Siboni
    Department of Medicine and Medical Specialties, Angelo Bianchi Bonomi Hemophlia and Thrombosis Center, University of Milan, IRCCS Maggiore Hospital, Mangiagalli and Regina Elena Foundation, Milan, Italy
    J Thromb Haemost 7:780-6. 2009
    ..There is no information on the health status and quality of life of elderly people with hemophilia born at a time when replacement therapy was hardly available...
  19. ncbi Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors
    L Scalone
    Centre of Pharmacoeconomics, Department of Pharmacological Sciences, University of Milan, and Department of Internal Medicine and Dermatology, Mangiagalli Hospital Foundation, Milan, Italy
    Haemophilia 12:154-62. 2006
    ....
  20. ncbi Melanocortin peptides inhibit production of proinflammatory cytokines in blood of HIV-infected patients
    A Catania
    Third Division of Internal Medicine, IRCCS Ospedale Maggiore, Milano, Italy
    Peptides 19:1099-104. 1998
    ..These results suggest that stimulation of melanocortin receptors in inflammatory cells could be a novel way to reduce production of cytokines that promote HIV replication...
  21. ncbi Differences between patients', physicians' and pharmacists' preferences for treatment products in haemophilia: a discrete choice experiment
    L G Mantovani
    Centre of Pharmacoeconomics, Department of Pharmacological Sciences, University of Milan, Italy
    Haemophilia 11:589-97. 2005
    ..Our study provides evidence of the differences between different stakeholders in the preferences towards haemophilia replacement therapy, indicating that different opinions should be taken into account when planning optimal care...
  22. ncbi Long-term safety and feasibility of arteriovenous fistulae as vascular accesses in children with haemophilia: a prospective study
    Elena Santagostino
    Department of Internal Medicine, A Bianchi Bonomi Haemophilia and Thrombosis Centre, IRCCS Maggiore Hospital and University of Milan, Milan, Italy
    Br J Haematol 123:502-6. 2003
    ..This study demonstrates that the use of AVF in haemophiliacs enabled long-term treatment at home in all patients but one...
  23. ncbi Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group
    P M Mannucci
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital, Milan, Italy
    Ann Intern Med 120:1-7. 1994
    ..To determine whether an outbreak of hepatitis A virus (HAV) infection that occurred in 52 patients with hemophilia in Italy was acquired through infusion of contaminated factor VIII or through environmental enteric transmission...
  24. ncbi State of care for hemophilia in pediatric patients
    Elena Santagostino
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital and University of Milan, Milan, Italy
    Paediatr Drugs 4:149-57. 2002
    ..Subcutaneous venous ports have been used in patients with hemophilia if peripheral veins could not be frequently accessed; however, the risk of infection is an important limit to their use...
  25. ncbi Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers)
    P M Mannucci
    A. Bianchi Bonomi Hemophilia and Thrombosis Centre, Department of Medicine and Medical Specialties, University of Milan, Italy
    Haemophilia 13:65-8. 2007
  26. ncbi Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients
    A Gringeri
    Hemophilia and Thrombosis Center Angelo Bianchi Bonomi, IRCCS Maggiore Hospital, Milan, Italy
    J Hum Virol 1:293-8. 1998
    ..Tat toxoid has been assayed for safety and immunogenicity in seropositive patients...
  27. ncbi From theory to practice: applying current clinical knowledge and treatment strategies to the care of hemophilia a patients with inhibitors
    Edward D Gomperts
    Children s Hospital Los Angeles, Division of Hematology Oncology, 4650 Sunset Blvd, M S 54, Los Angeles, California 90027, USA
    Blood Rev 22:S1-11. 2008
    ....
  28. ncbi A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study
    Jan Astermark
    Department for Hematology and Coagulation Disorders, Malmö University Hospital SE 205 02 Malmö, Sweden
    Blood 109:546-51. 2007
    ..This trial was registered at www.clinicaltrials.gov as #NCT00166309...
  29. ncbi New approaches to using FEIBA in the treatment of inhibitor patients
    Erik Berntorp
    Malmo University Hospital, Malmo, Sweden
    Semin Thromb Hemost 32:22-7. 2006
    ..Hemostasis is difficult to achieve in these patients and new treatment options are being explored. Similarly challenging are refractory bleeds, the management of which is likely to benefit from a systematic treatment approach...
  30. ncbi Effect of clotting factors concentrates on lymphocyte and neutrophil function in vitro
    Massimo Ghio
    Department of Internal Medicine (DIMI, University of Genova, Italy
    Thromb Haemost 89:365-73. 2003
    ....
  31. ncbi Immunogenicity of factor VIII concentrates in patients with hemophilia: a randomized clinical trial is warranted
    Alessandro Gringeri
    Blood 110:3084; author reply 3085. 2007
  32. ncbi A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation
    Christopher A Ludlam
    Department of Haematology, Royal Infirmary of Edinburgh, Edinburgh, UK
    Br J Haematol 120:808-13. 2003
    ....